Cytokinetics (CYTK) January calls and puts active
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Wall Street bullish on Cytokinetics (CYTK) following positive trial results
December 28, 2023 7:55 AM ESTCytokinetics (NASDAQ: CYTK) shares surged more than 82% Wednesday on the back of the positive results from its experimental heart treatment study.
Cytokinetics revealed that in a key Phase 3 study, its drug, Aficamten, "significantly improved exercise capacity compared to placebo." Here's how Wall Street analysts reacted to the news:
Barclays analyst Carter Gould raised the firm's price target for CYTK to $100 per share... More
